PARP

poly ADP ribose polymerase

PARP

PARP Isoform Specific Products:

PARP Isoform Comparison

PARP Related Products (368)
Antibodies (11)
PARP Isoform Comparison

By Effects:	Inhibitors (298) Agonists (2) Degraders (6) Activators (27) Inducers (12)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-16106A

(8R,9S)-Talazoparib	Inhibitor	98.28%
(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an PARP1 inhibitor, with an IC₅₀ of 144 nM.

HY-N1970

5,7-Dihydroxychromone	Activator	99.94%
5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved PARP in 6-OHDA-induced SH-SY5Y cells.

HY-117889

PARP14 inhibitor H10	Inhibitor	98.04%
PARP14 inhibitor H10, compound H 10, is a selective inhibitor against PARP14 (IC₅₀=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis.

HY-10619D

Niraparib (R-enantiomer)	Inhibitor	99.69%
Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent PARP1 inhibitor with IC₅₀ of 2.4 nM.

HY-13326

ASP3026		99.88%
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research.

HY-120115

PARPi-FL	Inhibitor	99.74%
PARPi-FL (Olaparib-bodipy FL) is a small-molecule fluorescent inhibitor of PARP1 that can specifically bind to PARP1. PARPi-FL can be used as a fluorescent imaging agent for tumor detection, diagnosis, and surgical guidance.

HY-114324

PROTAC PARP1 degrader	Inhibitor	99.74%
PROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. PROTAC PARP1 degrader induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader consists of E3 ubiquitinase ligand MDM2 ligand (HY-128836), blue part; target protein ligand PAPR1 ligand (HY-171543), pink part; PROTAC linker N3-PEG4-C2-NH2 (HY-128834), black part.

HY-115552

Simmiparib	Inhibitor	99.51%
Simmiparib is a highly potent and orally active PARP1 and PARP2 inhibitor with IC₅₀ values of 1.75 nM and 0.22 nM, respectively. Simmiparib has more potent PARP1/2 inhibition than its parent Olaparib (HY-10162). Simmiparib induces DNA double-strand breaks (DSB) accumulation and G2/M arrest in homologous recombination repair (HR)-deficient cells, thereby inducing apoptosis. Simmiparib exhibits remarkable anticancer activities in cells and nude mice bearing xenografts.

HY-132297A

PARP1-IN-5 dihydrochloride	Inhibitor
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.

HY-10614

A-966492	Inhibitor	99.95%
A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

HY-122661

Mefuparib hydrochloride	Inhibitor	98.62%
Mefuparib hydrochloride (MPH) is an orally active, substrate-competitive and selective PARP1/2 inhibitor with IC₅₀s of 3.2 nM and 1.9 nM, respectively. Mefuparib hydrochloride induces apoptosis and possesses prominent anticancer activity in vitro and in vivo.

HY-110077

API-1	Inducer	99.62%
API-1 is a potent selective Akt/PKB inhibitor that reduces the level of phosphorylated Akt (IC₅₀ = 0.8 μM). API-1 binds to the PH domain and inhibits Akt membrane translocation. API-1 induces c-FLIP degradation. API-1 reduces cell proliferation and induces apoptosis. API-1 decreases tumor growth in mouse xenograft model.

HY-148754

PARP10-IN-3	Inhibitor	98.89%
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on PARP2 and PARP15 with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively.

HY-W051513

2-Methylquinazolin-4-ol	Inhibitor	99.98%
2-Methylquinazolin-4-ol is a potent competitive poly(ADP-ribose) synthetase inhibitor, with a K_i of 1.1 μM. 2-Methylquinazolin-4-ol mammalian aspartate transcarbamylase (ATCase) inhibitor, with 0.20 mM.

HY-146502

PARP10/15-IN-3	Inhibitor	99.98%
PARP10/15-IN-3 (Compound 8a) is a potent PARP10 and PARP15 dual inhibitor with IC₅₀ values of 0.14 µM and 0.40 µM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from apoptosis.

HY-10619E

Niraparib tosylate hydrate	Inhibitor	99.97%
Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity.

HY-149800

PARP-1-IN-3	Inhibitor	99.30%
PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer.

HY-N1931

Epifriedelanol	Inhibitor	≥98.0%
Epifriedelanol is a triterpenoid found in the root bark of Ulmus davidiana. Epifriedelanol induces apoptosis in DU145 cells. Epifriedelanol has antitumor and anti-inflammatory activities. Epifriedelanol inhibits cellular senescence in human primary cells.

HY-113352

7-Methylguanine	Inhibitor	99.97%
7-Methylguanine is an orally active and competitive PARP-1 inhibitor with a K_i value of 61 μM. 7-Methylguanine is a metabolite of nucleic acids. 7-Methylguanine has anticancer activity against uterine sarcoma and colon adenocarcinoma. 7-Methylguanine is used as a probe for protein-DNA interactions.

HY-160937

AZD-9574-acid	Inhibitor
AZD-9574-acid (70D), a PPAR-1 inhibitor, can be used for the synthesis of PROTAC (CAS 2923686-70-6).

PARP Isoform Comparison

PARP

PARP1

PARP2

PARP3

PARP4

TNKS1/PARP5A

TNKS2/PARP5B

PARP7

PARP10

PARP14

PARP15

PARP12

PARP16

PARP Inducers, Degraders, Inhibitors & Activators

Product Name	PARP	PARP1	PARP2	PARP3	PARP4	TNKS1/PARP5A	TNKS2/PARP5B	PARP7	PARP10	PARP14	PARP15	PARP12	PARP16	Purity

Olaparib

PARP-1, IC₅₀: 5 nM

PARP-2, IC₅₀: 1 nM

tankyrase-1, IC₅₀: 1.5 μM

99.98%

XAV-939

ARTD1, IC₅₀: 5500 nM

ARTD2, IC₅₀: 479 nM

TNKS1, IC₅₀: 5 nM

TNKS2, IC₅₀: 2 nM

99.91%

Talazoparib

PARP1, Ki: 1.2 nM

PARP2, Ki: 0.87 nM

99.89%

Niraparib

PARP-1, IC₅₀: 3.8 nM

PARP-2, IC₅₀: 2.1 nM

PARP-3, IC₅₀: 1300 nM

V-PARP, IC₅₀: 330 nM

TANK-1, IC₅₀: 570 nM

99.96%

Saruparib

PARP1, IC₅₀: 3 nM

PARP2, IC₅₀: 1400 nM

99.76%

IRF1-IN-1

PARP-1

99.72%

IRF1-IN-2

PARP-1

99.83%

Rucaparib

PARP-1, Ki: 1.4 nM

99.97%

Chlorin e6

PARP-1

98.38%

Veliparib

PARP-1, Ki: 5.2 nM

PARP-2, Ki: 2.9 nM

99.78%

PJ34

PARP, IC₅₀: 110 nM

PARP-1, IC₅₀: 110 nM

PARP-2, IC₅₀: 86 nM

98.11%

KSQ-4279

PARP1

99.95%

RBN-2397

PARP-7, IC₅₀: 3 nM
PARP-7, Kd: 1 nM

99.86%

Pamiparib

PARP

99.97%

Dehydrocorydaline

PARP

99.77%

RBN012759

PARP4, IC₅₀: 10 μM

PARP7, IC₅₀: 4 μM

PARP10, IC₅₀: 1 μM

PARP14, IC₅₀: <3 nM

99.80%

Fluzoparib

PARP-1, IC₅₀: 1.46±0.72 nM

99.96%

SK-575

PARP1, IC₅₀: 2.30 nM

99.86%

Rucaparib phosphate

PARP-1, Ki: 1.4 nM

99.76%

Niraparib hydrochloride

PARP-1, IC₅₀: 3.8 nM

PARP-2, IC₅₀: 2.1 nM

PARP-3, IC₅₀: 1300 nM

V-PARP, IC₅₀: 330 nM

TANK-1, IC₅₀: 570 nM

99.41%

Niraparib tosylate

PARP-1, IC₅₀: 3.8 nM

PARP-2, IC₅₀: 2.1 nM

PARP-3, IC₅₀: 1300 nM

V-PARP, IC₅₀: 330 nM

TANK-1, IC₅₀: 570 nM

99.99%

NVP-TNKS656

PARP2, IC₅₀: 32 μM

TNKS2, IC₅₀: 6 nM

99.66%

3-Aminobenzamide

PARP, IC₅₀: 50 nM

99.99%

G007-LK

TNKS1, IC₅₀: 46 nM

TNKS2, IC₅₀: 25 nM

99.24%

AG14361

PARP-1, Ki: 0.5 nM

99.44%

Peiminine

PARP-1

99.94%

WIKI4

TNKS2, IC₅₀: 26 nM

99.93%

Paris saponin VII

PARP-1

99.96%

Stenoparib

PARP1, IC₅₀: 2 nM

PARP2, IC₅₀: 1 nM

TNKS1, IC₅₀: 50 nM

TNKS2, IC₅₀: 50 nM

≥98.0%

DPQ

PARP-1

≥99.0%

Triclabendazole

PARP

98.72%

Rucaparib monocamsylate

PARP-1, Ki: 1.4 nM

99.82%

PJ34 hydrochloride

PARP, IC₅₀: 110 nM

PARP-1, IC₅₀: 110 nM

PARP-2, IC₅₀: 86 nM

99.91%

BGP-15

PARP, IC₅₀: 120 μM

≥98.0%

RBN-3143

PARP1, IC₅₀: >100000 nM

PARP2, IC₅₀: >100000 nM

PARP3, IC₅₀: >100000 nM

PARP4, IC₅₀: 42700 nM

PARP10, IC₅₀: 1600 nM

PARP14, IC₅₀: 4 nM

PARP15, IC₅₀: 4200 nM

99.24%

AZD-2461

PARP1, IC₅₀: 5 nM

PARP2, IC₅₀: 2 nM

PARP3, IC₅₀: 200 nM

99.79%

OUL35

ARTD10/PARP10, IC₅₀: 329 nM

99.80%

OUL232

PARP1, IC₅₀: 15 μM

PARP2, IC₅₀: 10 μM

PARP3, IC₅₀: 50 μM

PARP4, IC₅₀: 11 μM

TNKS1, IC₅₀: 5.4 μM

TNKS2, IC₅₀: 10 μM

PARP7, IC₅₀: 83 nM

PARP10, IC₅₀: 7.8 nM

PARP14, IC₅₀: 300 nM

PARP15, IC₅₀: 56 nM

99.86%

UPF 1069

PARP-1, IC₅₀: 8 μM

PARP-2, IC₅₀: 0.3 μM

99.10%

Veliparib dihydrochloride

PARP-1, Ki: 5.2 nM

PARP-2, Ki: 2.9 nM

99.98%

iRucaparib-AP6

PARP1, DC₅₀: 82 nM

99.27%

DB008

PARP16, IC₅₀: 0.27 μM

98.78%

RK-287107

tankyrase-1, IC₅₀: 14.3 nM

tankyrase-2, IC₅₀: 10.6 nM

99.81%

ME0328

ARTD1/PARP1, IC₅₀: 6.3 μM

ARTD2/PARP2, IC₅₀: 10.8 μM

ARTD3/PARP3, IC₅₀: 0.89 μM

ARTD5/TNKS1, IC₅₀: 47.3 μM

ARTD6/TNKS2, IC₅₀: 34.3 μM

ARTD10/PARP10, IC₅₀: 71.3 μM

99.64%

Iniparib

PARP1

99.74%

1,5-Isoquinolinediol

PARP, IC₅₀: 0.18-0.37 μM

99.33%

AZ6102

PARP1, IC₅₀: 2 μM

PARP2, IC₅₀: 0.5 μM

TNKS1, IC₅₀: 3 nM

TNKS2, IC₅₀: 2 nM

99.65%

Venadaparib

PARP1, IC₅₀: 1.4 nM

PARP2, IC₅₀: 1 nM

98.11%

JW 55

TNKS1, IC₅₀: 1.9 μM

TNKS2, IC₅₀: 0.83 μM

98.95%

5,7,4'-Trimethoxyflavone

PARP

99.65%

MN-64

ARTD1, IC₅₀: 19.1 μM

ARTD2, IC₅₀: 39.4 μM

TNKS1, IC₅₀: 6 nM

TNKS2, IC₅₀: 72 nM

99.61%

OM-153

TNKS1, IC₅₀: 13 nM

TNKS2, IC₅₀: 2 nM

99.59%

N-Descyclopropanecarbaldehyde Olaparib

PARP

99.27%

NMS-P118

PARP-1, Kd: 9 nM

PARP-2, Kd: 1390 nM

99.54%

Gomisin N

PARP-1

99.94%

PARP7-IN-16

PARP-1, IC₅₀: 0.94 nM

PARP-2, IC₅₀: 0.87 nM

PARP-7, IC₅₀: 0.21 nM

99.91%

PARP7-IN-15

PARP7, IC₅₀: 0.56 nM

98.22%

Nesuparib

PARP2, IC₅₀: 2 nM

tankyrase-1, IC₅₀: 5 nM

tankyrase-2, IC₅₀: 1 nM

99.54%

PARP10/15-IN-1

PARP10, IC₅₀: 160 nM

PARP15, IC₅₀: 370 nM

K-756

TNKS1, IC₅₀: 31 nM

TNKS2, IC₅₀: 36 nM

99.25%

INO-1001

PARP

98.86%

BYK204165

hPARP-1, pIC₅₀: 7.35

mPARP-2, pIC₅₀: 5.38

98.66%

MSC2504877

PARP1, IC₅₀: 0.54 μM

98.50%

(8R,9S)-Talazoparib

PARP-1, IC₅₀: 144 nM

98.28%

5,7-Dihydroxychromone

PARP

99.94%

PARP14 inhibitor H10

PARP14, IC₅₀: 490 nM

98.04%

Niraparib (R-enantiomer)

PARP-1, IC₅₀: 2.4 nM

99.69%

ASP3026

PARP1

99.88%

PROTAC PARP1 degrader

PARP1

99.74%

Simmiparib

PARP1, IC₅₀: 0.74 nM

PARP2, IC₅₀: 0.22 nM

99.51%

PARP1-IN-5 dihydrochloride

PARP-1, IC₅₀: 14.7 nM

PARP-2, IC₅₀: 0.9 μM

A-966492

PARP-1, Ki: 1 nM

PARP-2, Ki: 1.5 nM

99.95%

Mefuparib hydrochloride

PARP1, IC₅₀: 3.2 nM

PARP2, IC₅₀: 1.9 nM

TNKS1, IC₅₀: 1.6 μM

TNKS2, IC₅₀: 1.3 μM

98.62%

API-1

PARP

99.62%

PARP10-IN-3

human PARP1, IC₅₀: >100 μM

human PARP2, IC₅₀: 1.7 μM

human PARP3, IC₅₀: >100 μM

human PARP4, IC₅₀: 7 μM

human TNKS1, IC₅₀: 21 μM

human TNKS2, IC₅₀: 6.5 μM

human PARP10, IC₅₀: 480 nM

human PARP14, IC₅₀: 41 μM

human PARP15, IC₅₀: 1.7 μM

human PARP12, IC₅₀: >10 μM

human PARP16, IC₅₀: >10 μM

98.89%

PARP10/15-IN-3

PARP10, IC₅₀: 0.14 μM

PARP15, IC₅₀: 0.40 μM

99.98%

Niraparib tosylate hydrate

PARP-1, IC₅₀: 3.8 nM

PARP-2, IC₅₀: 2.1 nM

PARP-3, IC₅₀: 1300 nM

V-PARP, IC₅₀: 330 nM

TANK-1, IC₅₀: 570 nM

99.97%

PARP-1-IN-3

PARP-1, IC₅₀: 0.25 nM

PARP-2, IC₅₀: 2.34 nM

99.30%

7-Methylguanine

PARP-1, Ki: 61 μM

99.97%

GeA-69

PARP14, Kd: 2.1 μM

99.91%

NMS-P515

PARP-1, Kd: 16 nM
PARP-1, IC₅₀: 27 nM (in Hela cells)

98.18%

TIQ-A

PARP2, IC₅₀: 210 nM

TNKS2, IC₅₀: 24 nM

PARP10, IC₅₀: >10 μM

PARP14, IC₅₀: >10 μM

PARP15, IC₅₀: 230 nM

99.85%

ART-IN-1

PARP2, IC₅₀: 19 μM

TNKS2, IC₅₀: 22 μM

PARP10, IC₅₀: 2.4 μM

PARP14, IC₅₀: >100 μM

PARP15, IC₅₀: 1.1 μM

98.91%

PARP7-IN-16 free base

PARP1, IC₅₀: 0.94 nM

PARP2, IC₅₀: 0.87 nM

PARP7, IC₅₀: 0.21 nM

99.40%

PROTAC PARP1 degrader-1

PARP-1

99.86%

PARP1-IN-29

PARP-1, IC₅₀: 6.3 nM

PARP10/15-IN-2

PARP10, IC₅₀: 0.15 μM

PARP15, IC₅₀: 0.37 μM

99.00%

DR2313

PARP-1, IC₅₀: 0.20 μM

PARP-2, IC₅₀: 0.24 μM

99.66%

YCH1899

PARP-1, IC₅₀: <0.001 nM

PARP-2, IC₅₀: <0.001 nM

PARP3, IC₅₀: 1.1 nM

PARP4, IC₅₀: 1.0 nM

TNKS1, EC₅₀: 3.8 nM

TNKS2, IC₅₀: 12.4 nM

PARP-7, IC₅₀: 7.3 nM

ARTD10/PARP10, IC₅₀: 10.8 nM

PARP14, IC₅₀: 35.914 μM

PARP15, IC₅₀: 51.623 nM

human PARP12, IC₅₀: 14.1 nM

99.39%

PARP-1-IN-2

PARP-1, IC₅₀: 149 ± 11.0 nM

99.48%

PARP1-IN-11

PARP1, IC₅₀: 0.082 μM

98.58%

PARP-2-IN-1

PARP-2, IC₅₀: 11.5 nM

99.56%

PARP/PI3K-IN-1

PARP-1, pIC₅₀: 8.22

PARP-2, pIC₅₀: 8.44

99.43%

PARP7-IN-17

PARP7

E7016

PARP

98.46%

PARP10-IN-2

human PARP1, IC₅₀: >100 μM

human PARP2, IC₅₀: 27 μM

human PARP3, IC₅₀: >100 μM

human PARP4, IC₅₀: >100 μM

human TNKS1, IC₅₀: >100 μM

human TNKS2, IC₅₀: >100 μM

human PARP10, IC₅₀: 3.64 μM

human PARP14, IC₅₀: >100 μM

human PARP15, IC₅₀: 11 μM

human PARP12, IC₅₀: >10 μM

human PARP16, IC₅₀: >10 μM

98.02%

Anticancer agent 43

PARP1

98.58%

Rucaparib tartrate

PARP-1, Ki: 1.4 nM

Rucaparib camsylate

PARP-1, Ki: 1.4 nM

PARP1-IN-5

PARP-1, IC₅₀: 14.7 nM

PARP-2, IC₅₀: 0.9 μM

Venadaparib hydrochloride

PARP1, IC₅₀: 1.4 nM

PARP2, IC₅₀: 1 nM

Rucaparib acetate

PARP-1, Ki: 1.4 nM

BPA-B9

PARP

Rucaparib hydrochloride

PARP-1, Ki: 1.4 nM

PARP1-IN-9

PARP1, IC₅₀: 30.51 nM

PARP-2-IN-3

PARP-2, IC₅₀: 0.07 μM

PARP1-IN-33

PARP1, IC₅₀: 0.41 nM

99.87%

OM-1700

TNKS1, IC₅₀: 127 nM

TNKS2, IC₅₀: 14 nM

TOPOI/PARP-1-IN-2

PARP-1, IC₅₀: 32.2 nM

PARP-2, IC₅₀: 2844 nM

Antitumor agent-170

PARP7, IC₅₀: 7.05 nM

ARTD10/PARP10-IN-1

ARTD1/PARP1, IC₅₀: 4.4 μM

ARTD10/PARP10, IC₅₀: 0.8 μM

ARTD8/PARP14, IC₅₀: 1.6 μM

ARTD7/PARP15, IC₅₀: 1.7 μM

PARP1/BRD4-IN-1

PARP1, IC₅₀: 49 nM

TC-E 5001

TNKS1, Ki: 79 nM

TNKS2, Ki: 28 nM

ZINC20906412

PARP10

PARP1/CDK12-IN-1

PARP1, IC₅₀: 34 nM

PARPYnD

PARP1

PARP2

PARP7-IN-22

PARP-7, IC₅₀: 0.6 nM

DLC-50

PARP1, IC₅₀: 1.2 nM

(rac)-Talazoparib

PARP1, Ki: 1.2 nM

PARP2, Ki: 0.87 nM

PARP1-IN-8

PARP-1, IC₅₀: 97 nM

99.29%

AZ0108

PARP1, IC₅₀: 0.03 μM

PARP2, IC₅₀: 0.03 μM

PARP3, IC₅₀: 2.8 μM

TNKS1, IC₅₀: 3.2 μM

PARP7-IN-12

PARP7, IC₅₀: 7.836 nM

PARP/EZH2-IN-2

PARP1, IC₅₀: 6.89 ± 0.7 nM

DPQ hydrochloride

PARP-1

PARP1/BRD4-IN-2

PARP1, IC₅₀: 197 nM

PARP1-IN-14

PARP1, IC₅₀: 0.6 ± 0.1 nM

PARP7-IN-23

PARP7

Tankyrase-IN-4

TNKS1, IC₅₀: 0.8 nM

PARP1-IN-21

PARP1

Anticancer agent 64

PARP

KSQ-4279 (gentisate)

PARP1

Antitumor agent-169

PARP7, IC₅₀: 2.5 nM

PROTAC PARP1 degrader-4

PARP1

Tankyrase-IN-3

TNKS1, IC₅₀: 22 nM

NDs-IN-1

hPARP-1

PARP-2

KU-0058948 hydrochloride

PARP-1, IC₅₀: 3.4 nM

PARP1-IN-18

PARP1, IC₅₀: 2.7 nM

PARP1-IN-34

PARP1, IC₅₀: 0.32 nM

PARP2, IC₅₀: 326 nM

PARP/EZH2-IN-1

PARP-1, IC₅₀: 6.87 nM

PARP7-IN-24

PARP7

PARP-1-IN-23

PARP-1, IC₅₀: 12.38 nM

PARP-2/1-IN-2

PARP1, Ki: 5 nM

PARP2, Ki: 2 nM

PARP1/BRD4-IN-3

PARP1, IC₅₀: 2019 nM

OUL245

PARP-1, IC₅₀: 570 nM

PARP2, IC₅₀: 44 nM

PARP3, IC₅₀: 8.8 μM

PARP4, IC₅₀: 6.0 μM

TNKS1, IC₅₀: 1.6 μM

TNKS2, IC₅₀: 370 μM

PARP10, IC₅₀: 2.9 μM

PARP14, IC₅₀: 6.7 μM

PARP15, IC₅₀: 2.0 μM

PARP1/c-Met-IN-1

PARP1, IC₅₀: 3.3 nM

PARP1-IN-22

PARP1

PARP1-IN-10

PARP1, IC₅₀: 50.62 nM (^[1])

SK-575-NEG

PARP-1, IC₅₀: 2.64 nM

PARP1/2/TNKS1/2-IN-1

PARP-1, IC₅₀: 0.25 nM

PARP-2, IC₅₀: 1.2 nM

TNKS1, IC₅₀: 13.5 nM

TNKS2, IC₅₀: 4.15 nM

PARP-1/HDAC-IN-1

PARP-1, IC₅₀: 68.90 nM

PARP1/2-IN-3

PARP-1, IC₅₀: 0.2235 nM

PARP1-IN-17

PARP-1

PARP-1/2/7-IN-1

PARP1

PARP2

PARP7

PARP1-IN-30

PARP1

ARTD10/PARP10-IN-2

ARTD1/PARP1, IC₅₀: 9.7 μM

ARTD10/PARP10, IC₅₀: 2.0 μM

ARTD8/PARP14, IC₅₀: >20 μM

ARTD7/PARP15, IC₅₀: >20 μM

PARP1-IN-20

PARP1, IC₅₀: 4.62 nM

PARP1-IN-12

PARP-1, IC₅₀: 2.99 nM

PARP1-IN-35

PARP1, IC₅₀: 0.2 nM

PARP2, IC₅₀: 122 nM

PROTAC PARP1 degrader-3

PARP-1, DC₅₀: 58.14 nM

CEP-9722

PARP-1, IC₅₀: 20 nM

PARP-2, IC₅₀: 6 nM

PARP7-IN-21

PARP7

CDK9/PARP-IN-1

PARP1, IC₅₀: 107 nM

EB-47

ARTD1/PARP1, IC₅₀: 45 nM

ST7710AA1

PARP-1, IC₅₀: 0.07 μM

KU-0058948

PARP-1, IC₅₀: 3.4 nM

Benzo[c][1,8]naphthyridin-6(5H)-one

PARP-1, IC₅₀: 0.311 μM

PARP1-IN-37

PARP1, IC₅₀: 24 nM

BSI-401

PARP-1

UPF-1035

PARP-1, IC₅₀: 9 μM

PARP-2, IC₅₀: 0.15 μM

EXQ-2d

TNKS1, IC₅₀: 48.8 nM

TNKS2, IC₅₀: 13.8 nM

KU-0058684

PARP-1, IC₅₀: 3.2 nM

WD2000-012547

PARP-1, pKi: 8.221

Name
Email *

	Sorry, but the email address you supplied was invalid.

PARP

PARP

PARP Isoform Specific Products:

PARP Isoform Specific Products:

PARP Related Products (368)

Antibodies (11)

PARP Isoform Comparison

PARP Related Products (368):